Editas Medicine (EDIT) Return on Capital Employed (2016 - 2025)
Editas Medicine (EDIT) reported Return on Capital Employed of 137.71% for Q3 2025, down 5720.0% year-over-year from 2.45% in Q3 2024, and up 1.76% quarter-over-quarter from 140.18% in Q2 2025.
Editas Medicine (EDIT) Return on Capital Employed (2016 - 2025) Analysis & Trends
Editas Medicine (EDIT) has 10 years of Return on Capital Employed data on file, last reported at 137.71% in Q3 2025.
- Return on Capital Employed for Q3 2025 came in at 137.71%, down 5720.0% year-over-year; the trailing twelve-month figure through Sep 2025 was 137.71% (down 5720.0% YoY), and the FY2024 annual result was 73.19%, down 3505.0% from the prior year.
- Return on Capital Employed advanced to 137.71% in Q3 2025 per EDIT's latest filing, from 140.18% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 23.69% in Q1 2021 and troughed at 140.18% in Q2 2025.
- A 5-year average of 59.13% and a median of 45.93% in 2024 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2021 and 2025: Return on Capital Employed soared 1361 bps in 2021, then tumbled 7721 bps in 2025.
- A 5-year view of Return on Capital Employed shows it stood at 29.7% in 2021, then slumped by 64 bps to 48.85% in 2022, then gained by 21 bps to 38.57% in 2023, then tumbled by 153 bps to 97.59% in 2024, then slumped by 41 bps to 137.71% in 2025.
- Business Quant data shows EDIT's Return on Capital Employed at 137.71% in Q3 2025, 140.18% in Q2 2025, and 113.43% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Editas Medicine | 262.77 Mn | 262.77 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -137.71% |
| Jun 30, 2025 | -140.18% |
| Mar 31, 2025 | -113.43% |
| Dec 31, 2024 | -97.59% |
| Sep 30, 2024 | -80.51% |
| Jun 30, 2024 | -62.97% |
| Mar 31, 2024 | -45.93% |
| Dec 31, 2023 | -38.57% |
| Sep 30, 2023 | -44.90% |
| Jun 30, 2023 | -48.16% |
| Mar 31, 2023 | -52.35% |
| Dec 31, 2022 | -48.85% |
| Sep 30, 2022 | -39.74% |
| Jun 30, 2022 | -32.86% |
| Mar 31, 2022 | -30.47% |
| Dec 31, 2021 | -29.70% |
| Sep 30, 2021 | -31.71% |
| Jun 30, 2021 | -24.10% |
| Mar 31, 2021 | -23.69% |
| Dec 31, 2020 | -25.60% |